Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirogabalin - Daiichi Sankyo Company

Next Previous
Drug Profile

Mirogabalin - Daiichi Sankyo Company

Alternative Names: DS 5565; Mirogabalin besilate; Mirogabalin besylate; TARLIGE; Tarlige

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Acetic acids; Amines; Aminobutyric acids; Analgesics; Cyclohexanecarboxylic acids; Gabapentinoids; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuropathic pain; Postherpetic neuralgia
  • No development reported Pain; Unspecified

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Japan (PO, Fast dissolve)
  • 31 Jan 2023 Preregistration for Neuropathic pain in China (PO) prior to January 2023
  • 31 Jan 2023 National Medical Products Administration accepts marketing application for mirogabalin for Neuropathic pain for review

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top